Name: Return on Assets (ROA)

Definition: ROA shows how efficiently the company turns everything it owns — its entire asset base — into net profit after all costs and taxes. A higher ROA means the business squeezes more profit from its assets. Lower ROA might reflect poor asset utilization or heavy reliance on expensive financing.

Interpretation:
• In '2021', VRAX's return on assets was -1643.0%, representing returns generated from total assets. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at -24.3%.
• In '2022', VRAX's return on assets was -3869.3%, representing returns generated from total assets. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at -36.5%. Industry average declined by 12.2% from previous year.
• In '2023', VRAX's return on assets was -110.7%, representing returns generated from total assets. The increase since '2022' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at -47.6%. Industry average declined by 11.1% from previous year.
• In '2024', VRAX's return on assets was -88.0%, representing returns generated from total assets. The increase since '2023' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at -51.9%. Industry average declined by 4.3% from previous year.
Overall, VRAX's return on assets has been volatile but showed an upward trend over the past 4 years.

Formula: ROA = Net Income / Total Assets

Good Range: Commonly 5%-15%.